1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Blueprint Presents Positive Ayvakit Data, But Commercial Debate Could Continue

 
• By Alaric DeArment

Detailed data in indolent systemic mastocytosis show improvement across primary and key secondary endpoints, but analysts pointed to lower improvement on symptoms outside of those affecting the skin.  

Blueprint unveiled detailed data for the Phase III PIONEER study of Ayvakit in indolent systemic mastocytosis • Source: Shutterstock

Blueprint Medicines Corporation’s presentation of full data from the Phase III PIONEER study of Ayvakit (avapritinib) in indolent systemic mastocytosis (ISM) bolsters the drug’s chances of winning approval while allaying some – but not all – of the concerns about its commercial potential in that disease amid a debate that arose when the company announced topline results from the study in 2022.

The biotech presented the data on 26 February at the American Academy of Allergy, Asthma & Immunology (AAAI) meeting. They...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Alkermes Two-For-Two In Narcolepsy As Alixorexton Succeeds In NT2 Trial

 
• By Alaric DeArment

The drugmaker plans to move into Phase III development of the drug, which has now posted positive Phase II results in narcolepsy types 1 and 2.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

enGene’s Detalimogene On Track For H2 2026 FDA Filing In NMIBC

 
• By Alaric DeArment

The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.

A Week Is A Long Time In Biotech, Just Ask Galecto

 
• By Kevin Grogan

A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.

More from R&D

AnaptysBio Scraps Rosnilimab Ulcerative Colitis Trial After Phase II Miss

 
• By Sushmita Panda

The biopharma plans to advance the PD-1 agonist in rheumatoid arthritis despite its failure in ulcerative colitis.

Neurocrine’s Depression Drug Misses In Phase II

 
• By Andrew McConaghie

Small study fails to turn up efficacy signals in the major depressive disorder candidate, leaving Neurocrine with one remaining depression candidate in development.

Beijing Mabworks Scores World-First Phase III Win In Membranous Nephropathy

 
• By Dexter Jie Yan

In a world-first, Beijing Mabworks has scored a Phase III clinical win for its novel anti-CD20 antibody in the treatment of primary membranous nephropathy. However, multiple global contenders including Roche are threatening to come from behind in the race.